Lenvatinib + Pembrolizumab + Oral Placebo + IV Placebo
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Hepatocellular
Conditions
Carcinoma, Hepatocellular
Trial Timeline
May 22, 2020 → Mar 25, 2026
NCT ID
NCT04246177About Lenvatinib + Pembrolizumab + Oral Placebo + IV Placebo
Lenvatinib + Pembrolizumab + Oral Placebo + IV Placebo is a phase 3 stage product being developed by Eisai for Carcinoma, Hepatocellular. The current trial status is active. This product is registered under clinical trial identifier NCT04246177. Target conditions include Carcinoma, Hepatocellular.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Hepatocellular were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04246177 | Phase 3 | Active |
Competing Products
20 competing products in Carcinoma, Hepatocellular